Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptorum Group Limited - Class A Ordinary Shares (NQ: APM )

0.8649 +0.1313 (+17.90%)
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptorum Group Limited - Class A Ordinary Shares

< Previous 1 2 3 Next >
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
From Aptorum Group Limited
Via Business Wire
Aptorum Group Ltd. (NASDAQ: APM) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
Aptorum Group Ltd. (NASDAQ: APM) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
From Aptorum Group Limited
Via Business Wire
Aptorum Group Ltd. (NASDAQ: APM) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
From Aptorum Group Limited
Via Business Wire
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
From Aptorum Group Limited
Via Business Wire
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
From Aptorum Group Limited
Via Business Wire
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency
From Aptorum Group Limited
Via Business Wire
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update
From Aptorum Group
Via Business Wire
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
From Aptorum Group Limited
Via Business Wire
Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces 1-for-10 Reverse Stock Split
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
From Aptorum Group Limited
Via Business Wire
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)
From Aptorum Group Limited
Via Business Wire
Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
From Aptorum Group Limited
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.